샘플 요청 목록

 카트 문의
시장보고서
상품코드
1776824

과민성대장증후군 치료 시장 : 세계 산업 분석, 시장 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Irritable Bowel Syndrome Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
발행일: | 리서치사: Persistence Market Research | 페이지 정보: 영문 192 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Persistence Market Research는 최근 세계 과민성 대장 증후군 시장에 대한 종합적인 분석을 발표했습니다. 이 보고서는 시장 성장 촉진요인-동향-기회-과제 등 주요 시장 역학에 대한 철저한 평가와 함께 시장 구조에 대한 상세 인사이트를 제공합니다.

주요 인사이트

  • 과민성대장증후군 시장 규모(2025년) : 42억 달러
  • 시장 규모 예측(금액 기반, 2032년) : 74억 달러
  • 세계 시장의 성장률(CAGR, 2025-2032년) : 8.5%

과민성 대장 증후군 시장 - 분석 범위

과민성 대장 증후군 치료제 시장에는 변비 동반 IBS(IBS-C), 설사 동반 IBS(IBS-D), 혼합형(IBS-M) 등 IBS의 하위 유형을 관리하기 위해 고안된 다양한 약리학적 및 비약리학적 치료법이 포함됩니다. 치료제에는 진경제, 완하제, 지사제, 항우울제, 프로바이오틱스, 새로운 표적치료제 등이 있습니다. 이 시장은 병원, 소화기 클리닉, 재택치료를 대상으로 합니다. 성장의 원동력은 전 세계 IBS 유병률 증가, 위장 건강에 대한 인식 증가, 장내세균을 표적으로 하는 치료법의 기술 혁신의 진전입니다.

시장 성장 촉진요인:

세계 과민성 대장 증후군 치료제 시장은 좌식 생활습관, 스트레스, 식습관 불균형으로 인한 소화기 질환 발병률 증가 등 몇 가지 중요한 요인에 의해 주도되고 있습니다. 소비자의 인식이 높아지고 진단율이 높아짐에 따라 효과적인 증상 관리에 대한 수요가 증가하고 있습니다. 또한 장 지향성 항생제, 세로토닌 수용체 모듈러 등 치료 제제의 발전으로 환자의 예후와 치료 순응도가 향상되고 있습니다. 규제 당국의 신약 승인과 시판 중인 치료제에 대한 접근성 확대는 시장 확대를 더욱 촉진하고 있습니다.

시장 성장 억제요인:

유망 성장 전망에도 불구하고 IBS 치료제 시장은 몇 가지 문제에 직면해 있습니다. IBS의 병태생리에 대한 이해가 제한적이어서 결정적인 치료법 개발을 가로막고 있으며, 증상의 불균일성이 치료 접근법을 복잡하게 만들고 있습니다. 또한 특정 약물의 장기 사용에 따른 부작용과 근본적인 해결책의 부족으로 인해 더 광범위한 시장으로의 침투를 제한하고 있습니다. 신흥 국가에서는 전문 의료에 대한 접근성이 제한되어 있고, IBS 증상에 대한 인식이 낮기 때문에 진단과 치료의 보급에 걸림돌이 되고 있습니다.

시장 기회:

과민성대장증후군 치료 시장은 맞춤형 의료와 장뇌축에 대한 관심이 높아지면서 큰 성장 기회를 가져다 줄 것입니다. 마이크로바이옴 조절, 저 FODMAP 식단 등 식이 중재에 대한 분석으로 새로운 치료의 길이 열리고 있습니다. 모바일 건강 앱, 원격 진료 등 디지털 건강 툴은 환자 참여와 증상 추적을 강화하고 있습니다. 제약사 및 바이오테크놀러지 기업은 IBS 아형을 타겟으로 한 신약 파이프라인 및 임상시험에 대한 투자를 늘리고 있으며, 이는 향후 시장 판도를 형성할 것으로 예측됩니다.

이 보고서에서 답변을 얻을 수 있는 주요 질문

  • 과민성 대장 증후군 치료제 시장의 세계 성장을 가속하는 주요 요인은?
  • 각 지역의 치료 도입에 영향을 미치는 치료 유형과 환자 하위 그룹은 무엇인가?
  • 기술-약학 발전은 IBS 치료제의 전망을 어떻게 바꾸고 있는가?
  • IBS 치료제 시장의 주요 기업은 어떤 회사들이 있으며, 어떤 전략적 구상을 취하고 있는가?
  • 세계 IBS 치료제 시장의 새로운 동향과 향후 전망은?

목차

제1장 개요

제2장 시장 개요

  • 시장의 범위와 정의
  • 시장 역학
    • 촉진요인
    • 억제요인
    • 기회
    • 과제
    • 주요 동향
  • 거시경제 요인
    • 세계의 부문별 전망
    • 세계 GDP 성장 전망
  • COVID-19의 영향 분석
  • 예측 요인 : 관련성과 영향

제3장 부가가치 분석

  • 규제 상황
  • 파이프라인 분석
  • 제품 채택 분석
  • 밸류체인 분석
  • 제조업체의 주요 프로모션 전략
  • PESTLE 분석
  • Porter's Five Forces 분석

제4장 과민성대장증후군 치료 시장 전망 :

  • 주요 하이라이트
    • 시장 규모 예측(수량 기반)
    • 시장 규모와 전년대비 성장률(금액 기반)
    • 절대적 매출 기회
  • 시장 규모 분석과 예측(금액 기반)
    • 과거 시장 규모 분석(금액 기반, 2019-2024년)
    • 현재 시장 규모 분석과 예측(금액 기반, 2025-2032년)
  • 세계의 과민성대장증후군 시장 전망 : 제품별
    • 서론/주요 분석 결과
    • 과거 시장 규모 분석 : 제품별(금액 기반, 2019-2024년)
    • 시장 규모 분석과 예측 : 제품별(금액 기반, 2025-2032년)
      • 식이섬유 보충제
      • 지사제
      • 항콜린제·항경련약
      • 항우울제
      • 항생제
      • Alosetron
      • Lubiprostone
      • Linaclotide
      • NHE3
    • 시장 매력 분석 : 제품별
  • 세계의 과민성대장증후군 시장 전망 : 적응증별
    • 서론/주요 분석 결과
    • 과거 시장 규모 분석 : 적응증별(금액 기반, 2019-2024년)
    • 시장 규모 분석과 예측 : 적응증별(금액 기반, 2025-2032년)
      • 변비를 수반하는 과민성대장증후군
      • 설사를 수반하는 과민성대장증후군
      • 혼합형 과민성대장증후군
    • 시장 매력 분석 : 적응증별
  • 세계의 과민성대장증후군 시장 전망 : 유통 채널별
    • 서론/주요 분석 결과
    • 과거 시장 규모 분석 : 유통 채널별(금액 기반, 2019-2024년)
    • 시장 규모 분석과 예측 : 유통 채널별(금액 기반, 2025-2032년)
      • 병원 약국
      • 소매 약국
      • 드러그스토어
      • 온라인 약국·점포
      • 하이퍼마켓·슈퍼마켓
    • 시장 매력 분석 : 유통 채널별

제5장 세계의 과민성대장증후군 치료 시장 전망 : 지역별

  • 주요 하이라이트
  • 과거 시장 규모 분석 : 지역별(금액 기반, 2019-2024년)
  • 시장 규모 분석과 예측 : 지역별(금액 기반, 2025-2032년)
    • 북미
    • 유럽
    • 아시아태평양
    • 남아시아·오세아니아
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 매력 분석 : 지역

제6장 북미의 과민성대장증후군 치료 시장 전망 :

제7장 유럽의 과민성대장증후군 치료 시장 전망 :

제8장 동아시아의 과민성대장증후군 치료 시장 전망 :

제9장 남아시아·오세아니아의 과민성대장증후군 치료 시장 전망 :

제10장 라틴아메리카의 과민성대장증후군 치료 시장 전망 :

제11장 중동 및 아프리카의 과민성대장증후군 치료 시장 전망 :

제12장 경쟁 구도

  • 시장 점유율 분석(2025년)
  • 시장 구조
    • 경쟁 강도 맵 : 시장별
    • 경쟁 대시보드
  • 기업 개요(상세 : 개요, 재무, 전략, 최근 동향)
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Pfizer, Inc.
    • Abbott Laboratories
    • Novartis AG
    • AstraZeneca PLC
    • Ironwood Pharmaceuticals Inc. and Allergan Plc
    • Bausch Health Companies Inc.
    • GlaxoSmithKline, Plc.
    • Lexicon Pharmaceuticals, Inc.
    • Sucampo Pharmaceuticals, Inc.

제13장 부록

  • 분석 방법
  • 분석 전제
  • 두자어와 약어
KSA

Persistence Market Research has recently released a comprehensive report on the worldwide market for irritable bowel syndrome (IBS) treatment. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Irritable Bowel Syndrome Treatment Market Size (2025E): USD 4.2 Billion
  • Projected Market Value (2032F): USD 7.4 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 8.5%

Irritable Bowel Syndrome Treatment Market - Report Scope:

The irritable bowel syndrome treatment market encompasses a variety of pharmacological and non-pharmacological therapies designed to manage IBS subtypes, including IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed-type (IBS-M). Treatments include antispasmodics, laxatives, antidiarrheals, antidepressants, probiotics, and newer targeted therapies. The market caters to hospitals, gastroenterology clinics, and homecare settings. Growth is driven by increasing global prevalence of IBS, rising awareness regarding gastrointestinal health, and ongoing innovations in gut microbiome-targeted therapies.

Market Growth Drivers:

The global irritable bowel syndrome treatment market is propelled by several key factors, including rising incidences of digestive disorders driven by sedentary lifestyles, stress, and dietary imbalances. Growing consumer awareness and increasing diagnosis rates have elevated demand for effective symptom management. Additionally, advancements in treatment formulations, including gut-directed antibiotics and serotonin receptor modulators, are improving patient outcomes and treatment adherence. Regulatory approvals of new drugs and expanding access to over-the-counter treatments further fuel market expansion.

Market Restraints:

Despite promising growth prospects, the IBS treatment market faces several challenges. Limited understanding of IBS pathophysiology hampers definitive treatment development, and the heterogeneity of symptoms complicates therapeutic approaches. Furthermore, side effects associated with long-term use of certain medications and lack of curative solutions restrict broader market penetration. In emerging economies, limited access to specialized care and low awareness of IBS symptoms pose barriers to diagnosis and treatment uptake.

Market Opportunities:

The irritable bowel syndrome treatment market presents substantial growth opportunities driven by the rising interest in personalized medicine and the gut-brain axis. Research into microbiome modulation and dietary interventions, such as low FODMAP diets, is opening new therapeutic avenues. Digital health tools, including mobile health apps and remote consultations, are enhancing patient engagement and symptom tracking. Pharmaceutical and biotechnology companies are increasingly investing in novel drug pipelines and clinical trials targeting IBS subtypes, which is expected to shape the future market landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the irritable bowel syndrome treatment market globally?
  • Which treatment types and patient subgroups are influencing therapy adoption across different regions?
  • How are technological and pharmacological advancements reshaping the IBS treatment landscape?
  • Who are the key players in the IBS treatment market, and what strategic initiatives are they undertaking?
  • What are the emerging trends and future prospects in the global IBS treatment market?

Competitive Intelligence and Business Strategy:

These companies are investing in the development of novel agents such as guanylate cyclase-C agonists, chloride channel activators, and serotonin receptor antagonists. Strategic collaborations with academic institutions and licensing partnerships are fostering pipeline development. Furthermore, efforts to improve patient education and promote early diagnosis are critical to strengthening market penetration and patient outcomes.

Key Companies Profiled:

  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • Abbott Laboratories
  • Novartis AG
  • AstraZeneca PLC
  • Ironwood Pharmaceuticals Inc. and Allergan Plc
  • Bausch Health Companies Inc.
  • GlaxoSmithKline, Plc.
  • Lexicon Pharmaceuticals, Inc.
  • Sucampo Pharmaceuticals, Inc.

Irritable Bowel Syndrome Treatment Market Research Segmentation:

By Product

  • Fiber Supplements
  • Anti-diarrheal
  • Anticholinergic and Antispasmodic
  • Antidepressant
  • Antibiotics
  • Alosetron
  • Lubiprostone
  • Linaclotide
  • NHE3

By Indication

  • Irritable Bowel Syndrome with Constipation
  • Irritable Bowel Syndrome with Diarrhea
  • Irritable Bowel Syndrome with alternating Constipation and Diarrhea

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies and Stores
  • Hypermarkets and Supermarkets

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Irritable Bowel Syndrome Treatment Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Pipeline Analysis
  • 3.3. Product Adoption Analysis
  • 3.4. Value Chain Analysis
  • 3.5. Key Promotional Strategies by Manufacturers
  • 3.6. PESTLE Analysis
  • 3.7. Porter's Five Force Analysis

4. Irritable Bowel Syndrome Treatment Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Irritable Bowel Syndrome Treatment Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019-2024
    • 4.3.3. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Fiber Supplements
      • 4.3.3.2. Anti-diarrheal
      • 4.3.3.3. Anticholinergic and Antispasmodic
      • 4.3.3.4. Antidepressant
      • 4.3.3.5. Antibiotics
      • 4.3.3.6. Alosetron
      • 4.3.3.7. Lubiprostone
      • 4.3.3.8. Linaclotide
      • 4.3.3.9. NHE3
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Irritable Bowel Syndrome Treatment Market Outlook: Indication
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
    • 4.4.3. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
      • 4.4.3.1. Irritable Bowel Syndrome with Constipation
      • 4.4.3.2. Irritable Bowel Syndrome with Diarrhea
      • 4.4.3.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
    • 4.4.4. Market Attractiveness Analysis: Indication
  • 4.5. Global Irritable Bowel Syndrome Treatment Market Outlook: Distribution Channel
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
    • 4.5.3. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
      • 4.5.3.1. Hospital Pharmacies
      • 4.5.3.2. Retail Pharmacies
      • 4.5.3.3. Drug Stores
      • 4.5.3.4. Online Pharmacies and Stores
      • 4.5.3.5. Hypermarkets and Supermarkets
    • 4.5.4. Market Attractiveness Analysis: Distribution Channel

5. Global Irritable Bowel Syndrome Treatment Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Irritable Bowel Syndrome Treatment Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Product
    • 6.2.2. By Indication
    • 6.2.3. By Distribution Channel
  • 6.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Fiber Supplements
    • 6.4.2. Anti-diarrheal
    • 6.4.3. Anticholinergic and Antispasmodic
    • 6.4.4. Antidepressant
    • 6.4.5. Antibiotics
    • 6.4.6. Alosetron
    • 6.4.7. Lubiprostone
    • 6.4.8. Linaclotide
    • 6.4.9. NHE3
  • 6.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 6.5.1. Irritable Bowel Syndrome with Constipation
    • 6.5.2. Irritable Bowel Syndrome with Diarrhea
    • 6.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
  • 6.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Retail Pharmacies
    • 6.6.3. Drug Stores
    • 6.6.4. Online Pharmacies and Stores
    • 6.6.5. Hypermarkets and Supermarkets
  • 6.7. Market Attractiveness Analysis

7. Europe Irritable Bowel Syndrome Treatment Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Indication
    • 7.2.4. By Distribution Channel
  • 7.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Fiber Supplements
    • 7.4.2. Anti-diarrheal
    • 7.4.3. Anticholinergic and Antispasmodic
    • 7.4.4. Antidepressant
    • 7.4.5. Antibiotics
    • 7.4.6. Alosetron
    • 7.4.7. Lubiprostone
    • 7.4.8. Linaclotide
    • 7.4.9. NHE3
  • 7.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 7.5.1. Irritable Bowel Syndrome with Constipation
    • 7.5.2. Irritable Bowel Syndrome with Diarrhea
    • 7.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
  • 7.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Retail Pharmacies
    • 7.6.3. Drug Stores
    • 7.6.4. Online Pharmacies and Stores
    • 7.6.5. Hypermarkets and Supermarkets
  • 7.7. Market Attractiveness Analysis

8. East Asia Irritable Bowel Syndrome Treatment Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Indication
    • 8.2.4. By Distribution Channel
  • 8.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Fiber Supplements
    • 8.4.2. Anti-diarrheal
    • 8.4.3. Anticholinergic and Antispasmodic
    • 8.4.4. Antidepressant
    • 8.4.5. Antibiotics
    • 8.4.6. Alosetron
    • 8.4.7. Lubiprostone
    • 8.4.8. Linaclotide
    • 8.4.9. NHE3
  • 8.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 8.5.1. Irritable Bowel Syndrome with Constipation
    • 8.5.2. Irritable Bowel Syndrome with Diarrhea
    • 8.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
  • 8.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Retail Pharmacies
    • 8.6.3. Drug Stores
    • 8.6.4. Online Pharmacies and Stores
    • 8.6.5. Hypermarkets and Supermarkets
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Irritable Bowel Syndrome Treatment Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Indication
    • 9.2.4. By Distribution Channel
  • 9.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Fiber Supplements
    • 9.4.2. Anti-diarrheal
    • 9.4.3. Anticholinergic and Antispasmodic
    • 9.4.4. Antidepressant
    • 9.4.5. Antibiotics
    • 9.4.6. Alosetron
    • 9.4.7. Lubiprostone
    • 9.4.8. Linaclotide
    • 9.4.9. NHE3
  • 9.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 9.5.1. Irritable Bowel Syndrome with Constipation
    • 9.5.2. Irritable Bowel Syndrome with Diarrhea
    • 9.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
  • 9.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Retail Pharmacies
    • 9.6.3. Drug Stores
    • 9.6.4. Online Pharmacies and Stores
    • 9.6.5. Hypermarkets and Supermarkets
  • 9.7. Market Attractiveness Analysis

10. Latin America Irritable Bowel Syndrome Treatment Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Indication
    • 10.2.4. By Distribution Channel
  • 10.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Fiber Supplements
    • 10.4.2. Anti-diarrheal
    • 10.4.3. Anticholinergic and Antispasmodic
    • 10.4.4. Antidepressant
    • 10.4.5. Antibiotics
    • 10.4.6. Alosetron
    • 10.4.7. Lubiprostone
    • 10.4.8. Linaclotide
    • 10.4.9. NHE3
  • 10.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 10.5.1. Irritable Bowel Syndrome with Constipation
    • 10.5.2. Irritable Bowel Syndrome with Diarrhea
    • 10.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
  • 10.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Retail Pharmacies
    • 10.6.3. Drug Stores
    • 10.6.4. Online Pharmacies and Stores
    • 10.6.5. Hypermarkets and Supermarkets
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Indication
    • 11.2.4. By Distribution Channel
  • 11.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Fiber Supplements
    • 11.4.2. Anti-diarrheal
    • 11.4.3. Anticholinergic and Antispasmodic
    • 11.4.4. Antidepressant
    • 11.4.5. Antibiotics
    • 11.4.6. Alosetron
    • 11.4.7. Lubiprostone
    • 11.4.8. Linaclotide
    • 11.4.9. NHE3
  • 11.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 11.5.1. Irritable Bowel Syndrome with Constipation
    • 11.5.2. Irritable Bowel Syndrome with Diarrhea
    • 11.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
  • 11.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 11.6.1. Hospital Pharmacies
    • 11.6.2. Retail Pharmacies
    • 11.6.3. Drug Stores
    • 11.6.4. Online Pharmacies and Stores
    • 11.6.5. Hypermarkets and Supermarkets
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Pfizer, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Product
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Takeda Pharmaceutical Company Limited
    • 12.3.3. Pfizer, Inc.
    • 12.3.4. Abbott Laboratories
    • 12.3.5. Novartis AG
    • 12.3.6. AstraZeneca PLC
    • 12.3.7. Ironwood Pharmaceuticals Inc. and Allergan Plc
    • 12.3.8. Bausch Health Companies Inc.
    • 12.3.9. GlaxoSmithKline, Plc.
    • 12.3.10. Lexicon Pharmaceuticals, Inc.
    • 12.3.11. Sucampo Pharmaceuticals, Inc.

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제